Login to Your Account

4 + 8 = 2 (years)

Personalized cancer vaccines succeed in two early trials

By Anette Breindl
Senior Science Editor

Wednesday, July 5, 2017

Two groups reported that vaccinating melanoma patients with personalized, tumor-specific antigens led to progression-free survival in the majority of patients over roughly two years of follow-up. The results were reported in back-to-back papers in the July 6, 2017, issue of Nature.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription